Diflunisal is an NSAID used to treat mild to moderate pain, inflammation, osteoarthritis, and rheumatoid arthritis. Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs.
- Mechanism
- Curator reviewed
The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.
- Primary indication
- For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis.Curator reviewed · 4 structured indications
- Formula / weight
- C13H8F2O3 · 250.1976 g/mol (avg)
- First approval
- Canada, 2014 · United States, 1992 · European Union, 2025
- Code names
- MK 647
- Brand names
Resolves to
HUPFGZXOMWLGNK-UHFFFAOYSA-NSMILESOC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Diflunisal, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account